Brief: Helix Biopharma Q2 loss per share C$0.03

Helix Biopharma

17/03/2017 11:50

March 17 (Reuters) - Helix Biopharma Corp  HBP.TO  - 
    * Announces fiscal second quarter 2017 results and closing 
of private placement 
    * Q2 loss per share C$0.03 
    * Helix Biopharma Corp - "Will require additional financing 
in near term and in future" 
    * Cash balance of C$1.4 million, as at Jan 31, 2017, is 
insufficient to meet anticipated cash needs for working 
capital,capital expenditures 
    * Decided to substitute vinorelbine/cisplatin combination 
study going forward with study combining l-DOS47 with 
pemetrexed/carboplatin 
 
Source text for Eikon:  ID:nCCN3cJfHg  
Further company coverage:  HBP.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com))